This study aimed to identify factors influencing the choice of a new once-daily oral treatment for moderate to severe psoriasis and to understand patient views on treatment characteristics. Conducted between December 2021 and June 2022, the noninterventional survey included 882 US adults with moderate to severe psoriasis. The study collected demographic, clinical, and treatment preference data. The factors influencing the choice of a new oral treatment were analyzed using multivariable logistic regression, and treatment characteristics were ranked through bivariate comparisons.

The results showed that most participants (66.5%) were willing to start a new oral treatment, with 65% finding it less anxiety-inducing than injections or infusions. Those currently receiving tumor necrosis factor inhibitors or ustekinumab, or those with mild to severe psoriasis symptoms, were more likely to start a new oral treatment. The study concluded that the willingness to switch to a new oral treatment was influenced by current treatment type and psoriasis severity, with many patients perceiving oral treatments as a less anxiety-provoking option than injectable or infused therapies.

Reference: Armstrong AW, Jayade S, Rege S, et al. Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient Survey. Dermatol Ther (Heidelb). 2024 Feb;14(2):421-439. doi: 10.1007/s13555-023-01089-6. Epub 2024 Jan 22. PMID: 38252376; PMCID: PMC10891029.